title: Profiling of autoantibodies in sera of pancreatic cancer patients.
abstract: BACKGROUND
  Although autoantibodies to cancer antigens are candidates for biomarkers, no comprehensive studies to detect cancer-specific antibodies have been performed. This study identified autoantibodies in the sera of pancreatic cancer (PC) patients using proteomics based on a wheat germ cell-free protein production system.
  
  
  METHODS
  We constructed a biotinylated protein library of 2,183 genes. Interactions between biotinylated proteins and serum antibodies were detected by AlphaScreen® assay. Relative luminescence signals of each protein in 37 PC patients and 20 healthy controls were measured, and their sensitivity and specificity for PC were calculated.
  
  
  RESULTS
  Luminescence signals of nine proteins were significantly higher than those of healthy controls, with calcium and integrin binding 1 (CIB1) protein showing the greatest significance (p = 0.002). Sensitivity, specificity, positive predictive value and negative predictive value of CIB1 autoantibody alone for PC were 76, 70, 82, and 61 %, respectively, and 97, 35, 74, and 88 %, respectively, when the four most significant proteins were combined. Presence of these autoantibodies did not vary significantly with other clinicopathological characteristics.
  
  
  CONCLUSIONS
  Several autoantibodies, including CIB1, are potential biomarkers for PC.
authors.affiliation: Departments of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Nagayoshi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Nakamura
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Matsuoka
authors.forename: Takao
authors.initials: T
authors.lastname: Ohtsuka
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Mori
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kono
authors.forename: Teppei
authors.initials: T
authors.lastname: Aso
authors.forename: Noboru
authors.initials: N
authors.lastname: Ideno
authors.forename: Shunichi
authors.initials: S
authors.lastname: Takahata
authors.forename: Akihide
authors.initials: A
authors.lastname: Ryo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takeda
authors.forename: Tetsuhide
authors.initials: T
authors.lastname: Ito
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Oda
authors.forename: Yaeta
authors.initials: Y
authors.lastname: Endo
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Sawasaki
authors.forename: Masao
authors.initials: M
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002135:Calcium-Binding Proteins / Q000097:blood*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000276:immunology; D011379:Prognosis; D012680:Sensitivity and Specificity
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor; C109198:CIB1 protein, human; D002135:Calcium-Binding Proteins